Non-standard abbreviations:
ApoA1: apolipoprotein A-I β2m: beta-2-microglobulin α-F 1 , β-F 1 : alpha and beta subunits of F 1 domain of ATP synthase EBV-B: Epstein Barr Virus-immortalized B cell line TAP: transporter associated with antigen processing MHC-I: MHC class I antigens iNKR: inhibitory natural killer cell receptor for MHC class I antigens
Introduction
T lymphocytes expressing an antigen receptor (TCR) of the γδ type represent a small fraction (1-5%) of T cells in human blood and lymph nodes although they may be more abundant in mucosae-associated lymphoid tissues. Striking features of these lymphocytes include an activated cell phenotype and a biased TCR V gene repertoire varying with their tissue distribution, so that the vast majority of human peripheral γδ cells express a Vγ9/Vδ2 TCR variable region gene combination (see (Hayday, 2000; Pennington et al., 2005 ) for reviews). These Vγ9/Vδ2 T cells proliferate in vivo and in vitro in response to bacterial nonpeptidic phosphorylated antigens termed phosphoantigens (PAg) in a TCR-dependent manner. To date the most powerful natural phosphoantigen is hydroxy-dimethylallyl pyrophosphate (HDMAPP), a metabolite of the 1-deoxy-D-xylulose-5-phosphate (DOXP) pathway of isoprenoid biosynthesis in plants and bacteria. (Bukowski et al., 1998; Morita et al., 2007; Poupot and Fournie, 2004) . How the bacterial PAgs produced by infected cells are presented to T cells is poorly understood although evidence exist that this requires a cell-cell contact which can be between sister Vγ9/Vδ2 T cells (Bonneville and Fournie, 2005; Green et al., 2004; Lang et al., 1995; Morita et al., 1995) .
Vγ9/Vδ2 T cells are also activated by several tumoral cell lines including hematopoietic tumors Daudi (Burkitt's lymphoma), RPMI8226 (myeloma) and K562 (erythroleukemia), and solid tumors such as renal cell carcinomas which are frequently found to be associated with Vγ9/Vδ2 T cell infiltrates in vivo (Zocchi and Poggi, 2004) . Recent findings implicate ubiquitous endogenous phosphoantigens (isopentenyl pyrophosphate and dimethylallyl-pyrophosphate) in Vγ9/Vδ2 T cell activation by tumors. Indeed, their accumulation or depletion following modulation of the mevalonate pathway by aminobisphosphonates or statins leads to an increase or decrease of the stimulatory activity, respectively (Gober et al., 2003) . Again, activation by these metabolites is likely to require some form of antigen presentation by unknown structures.
We recently described the presence of components of the mitochondrial ATP synthase on the surface of tumor cells with stimulatory activity for Vγ9/Vδ2 lymphocytes (Scotet et al., 2005) . This structure, referred to as ecto-F 1 -ATPase (F 1 ) binds a soluble form of Apolipoprotein A-I (ApoA1) so that an F 1 -ApoA1 complex is frequently detected on the surface of stimulatory tumors. Moreover, purified soluble forms of F 1 and ApoA1 both specifically bind to a recombinant soluble Vγ9/Vδ2 TCR and the F 1 -ApoA1 complex is stimulatory for Vγ9/Vδ2 T cells when immobilized on polystyrene beads. These components could be involved in endogenous phosphoantigen presentation although there is still no direct evidence for this.
Cell surface expression of F 1 is not confined to tumor cells as several studies have shown the presence and enzymatic activity of F 1 on hepatocytes, keratinocytes or endothelial cells (Burrell et al., 2005; Champagne et al., 2006; Martinez et al., 2003; Moser et al., 1999) . In the present paper, we provide evidence that F 1 is more frequently expressed on the surface of tumoral and non tumoral cells than previously thought on the basis of immunofluorescence analyses and that a close association exists between F 1 and Major Histocompatibility Complex class I antigens (MHC-I). Indeed, when these antigens are highly expressed, they can prevent F 1 detection. Knowing that Vγ9/Vδ2 T cell activation is strictly controlled by activatory and inhibitory receptors for MHC-I antigens (Fisch et al., 1997; Halary et al., 1997; Poccia et al., 1997; Trichet et al., 2006) , this has important functional implications regarding the regulation of their antitumoral and inherent anti-self reactivity.
Material and methods

Tumor cell lines, cultures and antibodies
Cell lines are from the ATCC except the human β2m Daudi transfectant (Anne Quillet, Toulouse, France) and RCC7 (Anne Caignard, Villejuif, France). 721.221 (MHC-I deficient (Shimizu and De Mars, 1989) ) and Awells (IHW#9090) are EBV-B cell lines. ST-EMO (EBV-B) and ST-F1 (primary fibroblast) are derived from a TAP-deficient patient (provided by Henry de la Salle, Strasbourg, France). HD-F1 are normal primary foreskin fibroblasts obtained from Purpan Hospital pediatric surgery department (Toulouse, France). RMA is a murine T lymphoma and RMA-S is its TAP-deficient variant (Ljunggren and Karre, 1985) . Cell lines were cultivated in RPMI 1640 medium except for HepG2, primary fibroblasts and RCC7 (DMEM), supplemented with FCS, glutamine and antibiotics.
The monoclonal anti-α (clone 7H10, IgG 2b ) and anti-β (clone 3D5, IgG 1 ) F 1 -ATPase antibodies used for immunofluorescence were from Molecular Probes. For immunoblotting studies, anti-α-F 1 (clone 51, IgG2a) and anti-β-F 1 (clone 10, IgG 1 ) were from BD Biosciences. The anti-cytochrome c antibody (clone 7H8.2C12, IgG 2b ) was from R&D Systems. The anti-HLA-DR FITC antibody (Immu-257, IgG 1 ) and isotype controls were from Beckman-Coulter. The anti-CD19 antibody (clone LT19, IgG 1 ) was from Exbio (Prague, Czech Republic). The HC10 (anti-MHC-I free heavy chain) antibody (Stam et al., 1990 ) was kindly provided by Dr H.L Ploegh (Cambridge, MA). The W6/32 hybridoma (anti-HLA-class I) was obtained from ATCC. The anti-H-2K b D b was from Cedarlane Laboratories.
Induction of MHC-I expression by cytokines and flow cytometry analysis
Fibroblast cells and other adherent cell lines were plated the day before treatment on 6-well dishes. Control Daudi cells were grown in suspension. For MHC class-I induction experiments, IFN-γ and/or TNF-α (Biosource) were added to cell cultures (48h). Adherent cells were harvested using ice-cold PBS containing 10mM EDTA. Cells were then washed with PBS 5% FCS (FACS medium). Staining and washing were performed in FACS medium using a standard indirect immunofluorescence procedure. Primary mAbs and isotypic controls were used at the concentration of 5-10µg/ml. Secondary staining was performed using polyclonal goat F(ab)' 2 anti-mouse IgG-FITC (Dako Cytomation). Data were acquired on a FACScan flow cytometer (BD Biosciences).
Disruption of cell surface MHC-I by acid treatment
The procedure described by Dong et al. was used (Dong et al., 2003) with minor modifications. Briefly, cells were harvested, washed once in PBS and incubated for 1min on ice in 1ml of citrate-phosphate buffer (66mM NaH 2 PO 4 , 131mM citric acid, 1% BSA, pH 3) or PBS as a control. pH was neutralized by the addition of 9ml of PBS (pH 13), and cells were pelleted, washed once with FACS medium, and stained immediately for flow cytometry analysis or put back in culture.
Streptavidin pull-down and co-immunoprecipitation experiments
Biotinylation and precipitation of cell surface proteins was performed according to Altin et al (Altin and Pagler, 1995) with few modifications using the membrane-impermeant NHS-LC-biotin reagent (Pierce, 0.25mg/ml). Co-precipitation of F 1 components with MHC did not require cross-linking. After cell lysis (150mM NaCl, 1% Triton X-100, Tris 20mM, pH7.6, anti-proteases) and centrifugation (10000g, 15min, 4°C) to remove insoluble material, lysates were pre-cleared with CL4B-sepharose beads and incubated for 3h at 4°C with streptavidin-sepharose beads (GE Healthcare) or with protein G-sepharose beads previously incubated with mAbs (1µg). Proteins were eluted at 100°C in Laemmli buffer (5% 2-ΜΕ) and loaded for standard 12% SDS-PAGE and transferred to nitrocellulose. Immunodetection was performed using primary antibodies at 1µg/ml followed by a secondary goat anti-mouse IgG-Horse Radish Peroxidase-conjugated Ab (Mouse Trueblot, eBioscience, SanDiego, CA) or streptavidin-HRP (GE Healthcare) and chemiluminescence (Sigma Co.).
Confocal microscopy
HepG2 cells were seeded (10 6 cells/well, 48h) on collagen-I-coated round coverslips (Biocoat, BD Biosciences) in 6-wells culture plates. Cells were then washed and fixed (4% paraformaldehyde, 15min, 4°C) and coverslips were saturated (PBS plus 0.2% gelatin, 1h, room temperature). After addition of primary mAb (3D5, anti-βF 1 , IgG 1, 10µg/ml, 1hr, 4°C), samples were washed and stained with Alexa 568-conjugated anti-IgG 1 (Molecular Probes) and FITC-conjugated W6/32 mAb (IgG 2a ). After washing, coverslips were dried, mounted on slides (PBS, 90% glycerol, 2.5% DABCO) and examined using a LSM510 confocal microscope (Carl Zeiss). The absence of cross-reactivity of anti-IgG1 antibodies towards IgG2a was checked.
Results
Ecto-F 1 -ATPase and MHC-I expression by cytometry
We previously documented the expression of components of F 1 on the surface of cell lines sensitive to lysis by Vγ9/Vδ2 lymphocytes. Other studies have independently reported the presence of the same components on hepatocytes (Martinez et al., 2003) , endothelial cells (Chang et al., 2002; Moser et al., 1999) , adipocytes or keratinocytes (Burrell et al., 2005) . We have now extended these findings by the cytofluorometry analysis of several other tumoral and non tumoral cell lines (Fig.1) . In addition to Daudi and K562, renal carcinomas and HepG2 tumors, the α and β subunits of F 1 are readily detected on the surface of HeLa cells and primary fibroblasts. As previously reported, these components are very weakly or not detected on Raji cells, Jurkat cells, and most EBV-transformed Blymphoblastoid cells lines such as Awells, LG2, RPMI-8866 ( Fig.1 and data not shown) . Daudi cells barely express MHC class-I antigens due to the lack of the MHC-I light chain β2-microglobulin (β2m). Strikingly F 1 is undetectable on β2m-transfected Daudi cells which express high levels of MHC-I. F 1 is also detected on the TAP-deficient B-lymphoblastoid line ST-EMO which has a strongly reduced expression of MHC-I antigens due to abnormal peptide loading. Similar observations can be made with the murine T cell lymphoma RMA (F 1 -) and its TAP-deficient counterpart RMA-S (F 1 + ). This suggests that surface staining of F 1 components correlates with a lower level of MHC-I expression. The correlation is however not absolute since the MHC-I-deficient 721.221 B-EBV cell line does not stain for F 1 .
Biochemical detection of ecto-F 1 -ATPase
In order to examine the presence of ecto-F 1 components using a biochemical approach, cell surface proteins from F 1 + and F 1 -lines were biotinylated and solubilized membrane proteins were precipitated with streptavidin, separated on a polyacrylamide gel and immunoblotted with anti-α and anti-β-F 1 antibodies (Fig.2) . This confirmed the presence of the α and β-F 1 chains on the surface of Daudi and K562 cells. Strikingly, the same components were also present in the precipitates of surface proteins from cell lines staining negatively, Awells and Jurkat. As a control for a possible mitochondrial contamination of streptavidin precipitates, membranes were also immunoblotted with an anti-cytochrome c antibody. The absence of detection of cytochrome c in streptavidin precipitates indicates that mitochondrial contamination is unlikely to account for the detection of F 1 components. More likely, this suggests that F 1 is present on Jurkat and Awells cells but was not detected by flow cytometry.
MHC-I antigens mask ecto-F 1 -ATPase epitopes
The inverse correlation between F 1 and MHC-I detection suggests that MHC-I expression might interfere with F 1 detection. In order to confirm this hypothesis, we took advantage of the HD-F1 primary fibroblasts which stain strongly for α and β-F 1 . On this line, MHC-I antigens are expressed to a moderate level and can be strongly up-regulated in a dose dependent manner following culture in the presence of varying doses of interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α). Cytokine-treated cells were thus monitored for F 1 and MHC-I expression by FACS. The experiment depicted in Figure 3 shows that the β-F 1 chain staining progressively declines while MHC-I antigens are up-regulated on the HD-F1 cell surface. Optimal treatment with the TNF-α/IFN-γ cytokine combination leads to an about 65% reduction of β-F 1 staining while MHC-I expression is stimulated ~11 folds. Interestingly, the modulation of β-F 1 staining is more sensitive to TNF-α treatment than to IFN-γ treatment. Conversely, overall MHC-I antigens are up-regulated more strongly with IFN-γ than with TNF-α, in accordance with published observations (Johnson, 2003) . Similar results have been obtained using the HepG2 hepatocarcinoma line. When this cytokine treatment is applied to the MHC-I deficient lines Daudi and K562, this does not lead to significant variations of F 1 staining, indicating that the decrease in F 1 staining on fibroblasts or HepG2 cells is not due to a down modulation of β-F 1 on the cell surface following cytokine treatment (data not shown). However, these experiments do not formally exclude a coordinated inverse regulation of ecto-F 1 and MHC-I antigens.
Polakova et al. (Polakova et al., 1993) have previously shown that short acid treatment of mammalian cells at low pH promotes the dissociation of MHC-I antigens leading to the loss of antigenicity (Sugawara et al., 1987) and release of β2m so that acid-treated cells display essentially free MHC-I heavy chains. In an attempt to reveal ecto-F 1 -ATPase on the surface of MHC-I-high cells, we used this approach to disrupt MHC antigens. This treatment was applied to Raji cells, which support this treatment with no visible change in morphology as evaluated by the forward and side scatter analysis by FACS, without significant cell death monitored by trypan blue incorporation, and no cell permeabilization monitored by propidium iodide staining (data not shown). MHC-I conformation was evaluated by cell staining with W6/32 antibody which detects native MHC-I antigens and HC10 which reacts selectively with free heavy chains. Acid treatment of Raji cells leads to an ~80% decrease of native MHC-I expression whereas the presence of free heavy chains is increased ~10 folds. Concomitantly, the α and β-F 1 chains are revealed on the surface of acid treated cells whereas the staining for MHC-II or CD19 antigens, used as controls, are unchanged (Fig.4a,b) . Acidtreated cells are still viable and can be re-cultured. This leads to a fast re-expression of native MHC-I antigens with a full recovery at ~6h. This is accompanied by a concomitant decrease of β-F 1 staining (Fig.4c) . The same acid treatment performed on MHC-deficient K562 (F 1 + ) and 721.221(F 1 -) cells does not induce any significant change in F 1 subunits detection, indicating that this is not a staining artifact due to acid treatment (data not shown). As metabolic modulation of antigen expression is not possible in this experimental setting, we conclude that MHC-I dissociation reveals F 1 α and β epitopes on the surface of MHC-I-high cells. This is an indication of the close proximity of these structures on the cell surface.
Close association between ecto-F 1 -ATPase components and MHC-I
In order to obtain direct evidence for an interaction between ecto-F 1 and MHC-I, we attempted to co-precipitate the complexes from lysates of MHC-I-high cells. Cells were surface-biotinylated and lysed. MHC-I antigens were immunoprecipitated using the W6/32 antibody, putative complexes were dissociated on a denaturing polyacrylamide gel and immunoblotted for the detection of F 1 components (Fig.5) . Immunoprecipitation of MHC-I brings down several membrane proteins revealed by blotting with steptavidin among which proteins at ~50kDa membrane proteins. Immunoblotting of the membrane with an anti-α-F 1 antibody allows detection of a protein which migrates as the mitochondrial α-F 1 (55 kDa) detected in total cell lysates. Similarly, immunoblotting with an anti-β-F 1 antibody reveals that the β subunit (52 kDa) is also present in the MHC-I precipitate. This is a strong indication that ecto-F 1 and MHC-I antigens can be closely associated.
Finally, the co-localization of MHC-I and ecto-F 1 was analyzed by confocal microscopy using HepG2 cells on which the moderate MHC-I expression allows the detection of both complexes (Fig.6) . On these cells, β-F 1 staining reveals patch-like structures on the cell surface as already reported on other cell types (Bae et al., 2004; Kim et al., 2004) . Similar patches are also revealed with the anti-MHC-I although these antigens are also present on the remaining of the plasma membrane where they are more evenly distributed. Superimposition of MHC-I and F 1 images indicates that F 1 and MHC-I antibodies effectively co-localize on the plasma membrane but, unlike MHC antigens, F 1 seems to be present selectively in the patchlike structures.
Discussion
In this work we provide evidence that ecto-F 1 -ATPase components are present on the cell surface of several cell lines in close proximity to MHC-I antigens. This proximity is such that it prevents antibody detection of F 1 epitopes when MHC-I expression is sufficiently high. Moreover, MHC-I antigens co-precipitate with α and β-F 1 subunits. This reveals a direct contact between these structures. The first question which comes to mind is whether the size of the two complexes is compatible with these observations. Assuming that ecto-F 1 has a structural arrangement similar to that of mitochondrial F 1 -ATPase, the height of the ectodomain above the membrane would be 83 Å for the α3β3 domain plus 50 Å for the central stalk of the complex connecting the α3β3 domain to the intra-membrane F o domain (Stock et al., 2000) . The height of the extra-membrane domain of MHC-I molecules is 70 Å as determined by crystallographic analysis (Bjorkman et al., 1987) . There is thus a possible 20 Å overlap between the bottom part of the α3β3 domain and the top part of the MHC-I molecule. This putative overlapping region would then correspond to the C-terminal ends of α and β-F 1 . The epitopes recognized by the antibodies used in immuno-fluorescence studies are not known but it is quite possible that the putative overlapping region contains multiple antibody epitopes which can be masked by the interaction. The (αβ) 3 stoichiometry of the F 1 complex is compatible with the observation that the density of MHC-I molecules on the cell surface influences the number of available epitopes for antibody binding.
The tissue distribution of ecto-F 1 -ATPase is not known, essentially due to the lack of antibodies able to label this structure on paraffin-embedded tissues. Many cell types have now been found to express ecto-F 1 -ATPase and this raises the possibility that this complex could have a ubiquitous distribution at the surface of mammalian cells. Indeed the ecto-F 1 -ATPase is detected on hepatocarcinoma cells, renal cell carcinomas, myeloma cells and Burkitt's lymphoma cells. This is not limited to tumor cells as we and others have found it expressed on primary fibroblasts (Fig.1) , on primary hepatocyte cultures (Martinez et al., 2003) and HUVEC cells (Chang et al., 2002; Moser et al., 1999) . All these cell types display a low or moderate level of MHC-I antigens. On Raji and Jurkat cells, the presence of F 1 is revealed by MHC-I disruption.
On most EBV-transformed lymphoblastoid cell lines, F 1 expression is undetectable by cytometry. Until now, the only exception is the TAP-deficient ST-EMO lymphoblastoid B cell line which was derived from an immunodeficient patient and clearly expresses ecto-F 1 . One should notice that MHC-I expression on most EBV lines is so high that knock-down of β2m using the small interfering RNA method keep MHC-I levels above that of cells which are spontaneously F 1 + (data not shown). However MHC-I disruption by acid treatment of Awells cells can reveal F 1 expression (not shown) and α and β-F 1 chains can be labeled by surface biotinylation of these cells (Fig.2) . This indicates that F 1 is indeed present on the surface of at least some EBV-B cells. 721.221 may represent an exception as all attempts to detect F 1 have failed in spite of extremely low MHC-I expression.
Results from Daudi (β2m-deficient), ST-EMO and RMA-S (TAP-deficient) and their β2m + or TAP + counterparts , in conjunction with the effect of β2m disruption by acid treatment suggest that MHC-I structures masking F 1 epitopes are β2m-and TAP-dependent. Immunoprecipitation experiments suggest that they are also reactive with W6/32 and thus conventional MHC-Ia antigens (HLA-A,B,C) as well as MHC-Ib HLA-G,E are good candidates. They must be weakly or not expressed on fibroblasts and more readily induced by TNF-α than by IFN-γ on these cells as opposed to overall MHC-I antigens. They most probably have a murine counterpart as deduced from F 1 -masking on RMA cells. Previous studies have reported a differential IFN-γ inducibility for MHC-I loci. This is the case for HLA-B as compared to HLA-A and C (Hakem et al., 1989; Johnson, 2003) and for HLA-G as compared to HLA-B and C (Yang et al., 1996) whereas HLA-C is poorly inducible (Tibensky and Delovitch, 1990) . We are currently investigating whether specific isotypes preferentially interact with F 1 and whether non-conventional MHC-Ib antigens can also be part of complexes.
The nature of MHC-class I (or MHC-Ib) antigens interacting with F 1 is particularly relevant to Vγ9/Vδ2 T cell activation mechanisms. There is multiple evidence that Vγ9/Vδ2 T cells monitor MHC-class I and MHC-class Ib levels on the surface of tumors and cells presenting phosphoantigens. This is through their expression of HLA-class I-specific inhibitory receptors (iNKR) which bind conventional MHC-I molecules as well as HLA-E and G. They also express activatory receptors (such as NKG2D) which bind stress-induced MHC-like proteins MICA/B and proteins of the RAET1 family (Bacon et al., 2004) . However, as the latter are not associated to β2m, they probably do not play a role in F 1 epitope masking.
We have previously shown that the Vγ9/Vδ2 TCR binds to an F 1 -ATPase/ApoA1 complex and that this recognition leads to Vγ9/Vδ2 T cell activation. The close association between the TCR ligand and the inhibitory ligand which regulates its activity may represent an important way to efficiently control TCR activity. Moreover, the TCR ligand ApoA1 is detected on tumor cells and its presence correlates with the detection of β-F 1 and low MHC class-I expression (Scotet et al., 2005) . It is thus possible that soluble ApoA1 somehow competes with MHC-class I on F 1 and favors TCR binding when the MHC density is low. This may represent an important mechanism controlling Vγ9/Vδ2 T cell activation. Daudi, Awells, K562 and Jurkat cells were surface-biotinylated. Membrane proteins were precipitated with streptavidin-coated beads and separated by denaturing PAGE. Identical membranes were immunoblotted with anti-α-F 1 and HC10 (anti-MHC-I free heavy chains) antibodies or with anti-β-F 1 and anti-cytochrome c antibodies. Note that ~100 times more cells are used for streptavidin pull-downs than for total lysates (used as size controls for F 1 components). This explains why MHC bands are not detected in total lysates from Jurkat cells. Slight shifts in migration are due to the biotinylation of the surface proteins in streptavidin pull-downs. Non-permeabilized HepG2 cells were stained simultaneously for native MHC-class I antigens (A; red) and β-F 1 (B; green) as described in the Material and Methods section. Panel C shows the merge of green and red images so that structures which co-localize appear yellow. D: differential interference contrast (DIC) image. Control experiments (not shown) were perfomed to control the isotype specificity of secondary antibody used (see Material and Methods).
